TY  - BOOK
AU  - Ernstoff, Marc (ed)
AU  - Puzanov, Igor (ed)
AU  - Robert, Caroline (ed)
AU  - Diab, Adi (ed)
AU  - Hersey, Peter (ed)
TI  - SITC's Guide to Managing Immunotherapy Toxicity
SN  - 0826172148
PY  - 2019///
CY  - United States
PB  - Springer
KW  - Immunotherapy
KW  - Oncology
N1  - Overview of Anti-CLA-4 agents - ipilimunab and tremelimumab; Overview of PD-1 and PD-L1 inhibitors; Indication and toxicities of immune checkpoint inhibitor combinations; General principles of immune-related toxicities; Dermatologic toxicities - rash, mucosal irritation, and pruritus; Muskuloskeletal and rheumatologic toxicities; Immune-related gastrointestinal toxicities; Pneumotoxicity associated with immune checkpoint blockades; Immune-related endocrinopathies associated with immune checkpoint inhibitors; Neurologic adverse events and neurologic complications; Cardiovascular toxicities related to immune checkpoint inhibitors; Renal toxicities associated with immune checkpoint inhibitors; Haematologic toxicities of apparent immune-related origins; Ocular toxicities caused by immune dysregulation; Safety and regulation of immune checkpoint inhibitors in special patient populations; Cancer-related fatigue in patients of immune checkpoint inhibitor therapy; Cost-effectiveness and financial toxicity of new cancer therapies
N2  - SITC's Guide to Managing Immunotherapy Toxicity is a practical reference to managing side effects associated with FDA-approved cancer immunotherapy drugs
ER  -